Markets open

Biogen Inc.

BIIB · NASDAQ-GS

Sep 2026upcoming

Next quarter

Consensus is $2.87 EPS for Sep 2026 across 16 estimates, ranging $1.71 to $4.28.

BIIB Jun 2026

Reported Jul 29, 2026

Beat 18.42%

EPS estimate: $3.04
EPS actual: $3.60
Revenue estimate: —
Revenue actual: —
1-day move: -0.62%

Call highlights have not been generated for this quarter.

Symbol: BIIB
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: NASDAQ-GS

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

Key Issues

Bullish view

Biogen handily beat analyst estimates on both the top and bottom lines, indicating that operating performance may be stronger than expectations embedded in the stock.

Bearish view

The evidence identifies only a single reported earnings beat and gives no detail on its magnitude, revenue mix, or durability; FY2025 net income was also below FY2024 despite higher revenue.